Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma.
The Swiss pharmaceutical company will collaborate with Zealand on petrelintide, a drug based on the hormone amylin that helps people feel fuller for longer, as it pushes further into the lucrative weight-loss market….
Read the full article here
